Rockefeller Capital Management
ACOR

Rockefeller Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Rockefeller Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8
Closed – – 4167
2022
Q4 		$0 Buy
+8
New +$93 ﹤0.01% 4343

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
DKP
Davidson Kempner Partners New York $5.16B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Rockefeller Capital Management's ACOR Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2023, closing a stake of 8 shares.

Rockefeller Capital Management first reported a position in ACOR in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 29 funds tracked by Wall St. Rank hold ACOR as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Acorda Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 8 Acorda Therapeutics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Acorda Therapeutics in Q4 2022 and held it in 1 quarter.
  • Rockefeller Capital Management's Acorda Therapeutics position peaked at $0 in Q4 2022.
  • 29 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.